Research programme: plasmid DNA therapeutics - Alma Bio Therapeutics

Drug Profile

Research programme: plasmid DNA therapeutics - Alma Bio Therapeutics

Latest Information Update: 07 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alma Bio Therapeutics
  • Class DNA
  • Mechanism of Action Heat-shock protein modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Crohn's disease
  • Research Rheumatic disorders

Most Recent Events

  • 26 Jun 2017 Early research in Rheumatic disorders in France (unspecified route)
  • 26 Jun 2017 Preclinical trials in Crohn's disease in France (unspecified route)
  • 26 Jun 2017 Alma Bio Therapeutics plans a phase I trial for Crohn's disease in 2H 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top